Ultrasonography of the Vagus Nerve in Parkinson’s Disease

Nadin Fedtke 1, Otto W. Witte 1,2 and Tino Prell 1,2*

1 Department of Neurology, Jena University Hospital, Jena, Germany, 2 Center for Healthy Ageing, Jena University Hospital, Jena, Germany

Based on the topographic distribution of α-synuclein-enriched Lewy bodies, it has been hypothesized that Parkinson’s disease may start in the gastrointestinal tract and gain access to the central nervous system via the vagus nerve. Since ultrasonography is a powerful tool to study peripheral nerve disturbances, we conducted ultrasonography of the vagus nerve in 32 patients with Parkinson’s disease, 15 disease controls and 15 healthy controls. The cross-sectional area and echogenicity measured on transverse scans of the vagus nerve did not differ significantly between these groups. Therefore, the observed intraneuronal changes in Parkinson’s disease are not associated with ultrasonographic disruptions of the vagus nerve integrity.

HIGHLIGHTS
• We studied ultrasonography of the vagus nerve in 32 patients with Parkinson’s disease and in 15 disease controls and 15 healthy controls.
• The sonographic cross-sectional area measured using high-frequency linear array transducers did not differ significantly between both groups.
• Ultrasonography of the vagal nerve does not reflect cellular damage caused by α-synuclein-enriched Lewy bodies in nerves of patients with Parkinson’s disease.

Keywords: vagus nerve, sonography, cross-sectional area, Parkinson’s disease, polyneuropathy, bradykinesia, dysautonomia

INTRODUCTION

It has been hypothesized that neuropathological process that lead to Parkinson’s disease may start in the enteric nervous system and spread rostrocranial via the vagus nerve to the substantia nigra (1–3). This gut-brain transmission scenario is controversially discussed within the movement disorders community (4). Nevertheless, the pathological α-synuclein signature can be observed in the peripheral nervous system in patients with Parkinson’s disease (5).

Since high-frequency ultrasonography provides a valuable tool to study both peripheral nerves and the vagus nerve and is increasingly being used in the diagnosis of polyneuropathies (6), we aimed to answer the question whether patients with Parkinson’s disease have sonographic abnormalities in the vagus nerve.

METHODS

The study was approved by the local ethics committee and has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All patients gave their written informed consent. We performed standardized ultrasonography of the vagus nerve at the lateral margins of the anterior cervical region beneath the sternocleidomastoid muscle in 20 male and 12 female patients with Parkinson’s disease, 15 age-and sex-matched disease...
controls (6 stroke, 7 essential tremor, 2 headache) and 15 age-and sex-matched healthy controls (15 MHz, Toshiba Aplio 400). The nerve cross-sectional area (CSA) was determined by tracing the nerve area within the hyperechoic epineurium. Polyneuropathy was ruled out by means of additional nerve conduction studies and ultrasonography of the median nerve, tibial nerve and suralis nerve as previously described (7).

The Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS I–IV) and Hoehn and Yahr staging were used to evaluate motor and non-motor symptoms. The distinct PD subtypes (postural instability and gait difficulty-predominant type, indeterminate/mixed type and tremor-type) and bradykinesia score were calculated from the MDS-UPDRS as previously described (9, 10).

The SPSS statistical computer package (version 23.0; IBM Corporation, Armonk, NY, USA) was used for all statistical analyses. All continuous data are presented as mean ± standard deviation. Categorical variables are presented as percentages (%). Prior to statistical analysis, data were checked for outliers and for normality using the Shapiro-Wilk’s test. For comparisons of CSA between the three groups an ANOVA with Bonferroni correction was used. T-test was used to compare patients with and without constipation. Pearson correlation was used for normally distributed values. Statistical significance was set at \( P < 0.05 \).

RESULTS

Patients with Parkinson’s disease were characterized by a mean age of 70 ± 6 years and moderate motor impairment (mean MDS-UPDRS III = 33 ± 12, mean UPDRS II = 17 ± 7). Of note, 3.1% of patients were mildly, 62.5% moderately and 34.4% severely affected (Hoehn and Yahr stage I, II-III, IV respectively). The right CSA of the vagal nerve was significantly larger than the left (\( P = 0.021 \)). The CSA (mm\(^2\)) measured on transverse scans of the vagal nerve did not differ significantly between healthy controls (right = 2.7 ± 0.7, left = 2.4 ± 0.7), disease controls (right = 2.7 ± 0.6, left = 2.3 ± 0.4) and patients with Parkinson’s disease (right = 2.9 ± 0.7, left = 2.6 ± 0.7) (ANOVA, Bonferroni correction, \( P > 0.05 \)). Figure 1 shows an ultrasonographic example of the vagus nerve in a patient with Parkinson’s disease. In addition, nerve echogenicity, like the fascicle appearance, did not differ between the three groups. CSAs of the vagal nerves did not significantly correlate with disease duration, Hoehn and Yahr stage, and the tremor/PIGD index. The CSAs of the vagal nerve did not significantly differ between patients with and without constipation (MDS-UPDRS item 1.11). However, the CSA of right vagus nerve was significantly positively correlated with the bradykinesia score (right Pearson’s \( r = 0.537, P = 0.003 \); left Pearson’s \( r = 0.348, P = 0.069 \)).

There was no significant difference of the CSA in the median, tibial and suralis nerves between patients with Parkinson’s disease and controls (anova, Bonferroni correction, \( P > 0.05 \)).

DISCUSSION

Ultrasoundography of the vagus nerve can support the diagnosis of several neuropathies. A slightly reduced CSA of the vagus nerve was observed in patients with diabetes mellitus compared to healthy controls and this was interpreted as vagal atrophy or degeneration (11). In contrast, vagal hypertrophy or focal enlargement can occur in immune-mediated or vasculitic neuropathies (8, 12). However, in patients...
with Parkinson’s disease, high-resolution ultrasonography did not reveal detectable structural disturbances in the vagal nerve in comparison to healthy controls. According to the known reference values the right vagus nerve was larger than the left one (13). The CSA of the right vagal nerve correlated with the bradykinesia assessed by the MDS-UPDRS III. Indeed, the bradykinesia-dominant subtypes seem to be associated with widespread Lewy body pathology in the sympathetic central nervous system (14, 15). However, this correlation cannot be fully explained and must be interpreted with caution because of the absence of the difference to controls and the natural variability of nerve size.

The study has several limitations. We used state of the art high-resolution ultrasonography but we cannot rule out that a higher-resolution would be able to detect structural disturbances in the vagal nerve of patients with Parkinson’s disease. Nevertheless, our study showed that there is no prominent nerve enlargement as known from immune-mediated neuropathies. For example, Grimm et al. (12) observed a focal swelling of both vagal nerves of up to 9 mm² CSA in the left and 6 mm² CSA in the right. In comparison, as in our study, the normal area size lies between 2 and 3 mm² (7, 8, 13).

In conclusion the sonographic structure of the vagus nerve is unremarkable and ultrasonography of the vagus nerve seems to have no potential as biomarker in Parkinson’s disease.

AUTHOR CONTRIBUTIONS

NF and TP: design of the study; NF and TP: acquisition and analysis of data; NF and TP: drafting; OW: revising work critically for important intellectual content.

ACKNOWLEDGMENTS

We thank Nasim Kroegel for proofreading.

REFERENCES

1. Hawkes CH, Del Tredici K, Braak H. Parkinson’s disease: a dual-hit hypothesis. Neuroreport Appl Neurobiol. (2007) 33:599–614. doi: 10.1011/j.1365-2990.2007.00874.x
2. Holmqvist S, Chutna O, Boussot L, Aldrin-Kirk P, Li W, Björklund T, et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol. (2014) 128:805–20. doi: 10.1007/s00401-014-1343-6
3. Svensson E, Horvath-Puhó É, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer P, et al. Vagotomy and subsequent risk of Parkinson’s disease. Ann Neurol. (2015) 78:522–9. doi: 10.1002/ana.24448
4. Lionnet A, Leclair-Visonneau L, Neunlist M, Murayama S, Takao M, Adler CH, et al. Does Parkinson’s disease start in the gut? Acta Neuropathol. (2018) 135:1–12. doi: 10.1007/s00401-017-1777-8
5. Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White C, L. III, et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol. (2014) 119:689–702. doi: 10.1007/s00401-010-0664-3
6. Grimm A, Winter N, Rattay TW, Härtig F, Dammeier NM, Auffenberg E, et al. The influence of age and gender on motor and non-motor features of early Parkinson’s disease: initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. Parkinsonism Relat Disord. (2014) 20:99–105. doi: 10.1016/j.parkreldis.2013.09.025
7. Tawfik EA, Walker FO, Cartwright MS, El-Hilaly RA. Diagnostic ultrasound of the vagus nerve in patients with diabetes. J Neuroimaging (2017) 27:589–93. doi: 10.1111/jon.12452
8. Grimm A, Décard BF, Bischof A, Axer H. Ultrasound of the peripheral nerves in systemic vasculitic neuropathies. For example, Grimm et al. (12) observed a focal swelling of both vagal nerves of up to 9 mm² CSA in the left and 6 mm² CSA in the right. In comparison, as in our study, the normal area size lies between 2 and 3 mm² (7, 8, 13). In conclusion the sonographic structure of the vagus nerve is unremarkable and ultrasonography of the vagus nerve seems to have no potential as biomarker in Parkinson’s disease.

10. Szewczyk-Krolowski K, Tomlinson P, Nithi K, Wade-Martins R, Talbot K, Ben-Shlomo Y, et al. The influence of age and gender on motor and non-motor features of early Parkinson’s disease: initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. Parkinsonism Relat Disord. (2014) 20:99–105. doi: 10.1016/j.parkreldis.2013.09.025
11. Grimm A, Rasenack M, Athanasopoulou I, Peters N, Fuhr P. Long-term observations in asymmetric immune-mediated neuropathy with vagus hypersensitivity using ultrasound of the nerves. J Neurol Sci. (2015) 356:205–8. doi: 10.1016/j.jns.2015.06.018
12. Pela JO, Belau E, Henn P, Hammer N, Classen J, Weise D. Sonographic evaluation of the vagus nerves: protocol, reference values, and side-to-side differences. Muscle Nerve (2018) 57:766–71. doi: 10.1002/mus.25993
13. Suzuki M, Urashima M, Oka H, Hashimoto M, Taira K. Cardiac sympathetic denervation in bradykinesia-dominant Parkinson’s disease. Neuroreport (2007) 18:1867–70. doi: 10.1097/WNR.0b013e3282f1ab33
14. Chung EL, Kim EG, Kim MS, Bae SK, Seog DH, Oh SJ, et al. Differences in myocardial sympathetic degeneration and the clinical features of the subtypes of Parkinson’s disease. J Clin Neurol. (2011) 18:922–5. doi: 10.1016/j.jocn.2010.12.024

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Fedtke, Witte and Prill. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.